ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Garner Discusses the myRisk Hereditary Cancer Test

Elizabeth Garner, MD, MPH
Published: Monday, Dec 16, 2013



Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Garner explains that myRisk is a genetic test that looks for mutations in 25 genes that are known to be associated with significantly elevated risk for cancer. There are eight major cancers that the test can detect, such as breast cancer, ovarian cancer, melanoma, and endometrial cancer.

The test allows physicians to increase the rate of detection for individuals that have mutations or who have hereditary cancer syndromes, Garner says. The increased ability to detect these patients allows these patients to better manage their health, in order to reduce their risk of developing cancer.

<<< View more from the 2013 SABCS Meeting



Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.

Garner explains that myRisk is a genetic test that looks for mutations in 25 genes that are known to be associated with significantly elevated risk for cancer. There are eight major cancers that the test can detect, such as breast cancer, ovarian cancer, melanoma, and endometrial cancer.

The test allows physicians to increase the rate of detection for individuals that have mutations or who have hereditary cancer syndromes, Garner says. The increased ability to detect these patients allows these patients to better manage their health, in order to reduce their risk of developing cancer.

<<< View more from the 2013 SABCS Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x